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Mutations in a-synuclein and Leucine-rich repeat
kinase 2 (LRRK2) are linked to autosomal dominant
forms of Parkinson’s disease (PD). However, little is
known about any potential pathophysiological inter-
play between these two PD-related genes. Here we
show in transgenic mice that although overexpression
of LRRK2 alone did not cause neurodegeneration,
the presence of excess LRRK2 greatly accelerated
the progression of neuropathological abnormalities
developed in PD-related A53T a-synuclein transgenic
mice. Moreover, we found that LRRK2 promoted the
abnormal aggregation and somatic accumulation of
a-synuclein in A53T mice, which likely resulted from
the impairment of microtubule dynamics, Golgi orga-
nization, and the ubiquitin-proteasome pathway. Con-
versely, genetic ablation of LRRK2 preserved the
Golgi structure and suppressed the aggregation and
somatic accumulation of a-synuclein, and thereby
delayed the progression of neuropathology in A53T
mice. These findings demonstrate that overexpres-
sion of LRRK2 enhances a-synuclein-mediated cyto-
toxicity and suggest inhibition of LRRK2 expression
as a potential therapeutic option for ameliorating
a-synuclein-induced neurodegeneration.
INTRODUCTION
Parkinson’s disease (PD) is characterized pathologically by
relatively selective loss of midbrain and brain stem catecholamin-ergicneurons and by deposition ofa-synuclein (a-syn) aggregates
in cell bodies and nerves (Nussbaum and Polymeropoulos, 1997).
Since mutations in both a-syn and Leucine-rich repeat kinase 2
(LRRK2) cause familial forms of PD that resemble sporadic PD
pathologically (Hardy et al., 2006), these genetic mutations
provide valuable molecular tools to study the pathogenesis of
PD. The etiology of PD remains elusive; however, it has been
generally accepted that the formation of a-syn aggregates is
a key step in the pathogenesis of PD (Trojanowski et al., 1998).
Mutations in the a-syn gene, including missense mutations
(A53T and A30P) and gene duplication/triplication, lead to the
development of early-onset familial PD (Hardy et al., 2006).
Furthermore, a-syn is a main component of abnormal intracel-
lular deposits known as Lewy bodies (LBs) and Lewy neurites
(LNs) found in PD brains (Spillantini et al., 1997). While both
wild-type (WT) and mutant a-syn form fibrillar aggregates,
PD-related a-syn mutations greatly accelerate the formation of
fibrils as compared with WT protein (Conway et al., 1998; Narhi
et al., 1999). a-syn aggregates cause various forms of cytotox-
icity, including impairment of proteasomal and lysosomal activi-
ties, disruption of ER-Golgi traffic and microtubule-based trans-
port, and dysfunction of mitochondria (Cooper et al., 2006;
Cuervo et al., 2004; Gosavi et al., 2002; Lee et al., 2006; Tanaka
et al., 2001). Because a-syn aggregates are detrimental to cells,
many studies on PD therapy are focused on identifying elements
that affect a-syn’s ability to form aggregates and fibrils (Savitt
et al., 2006).
Mutations in LRRK2 have been linked to both familial and
sporadic forms of PD (Paisan-Ruiz et al., 2004; Zabetian et al.,
2005; Zimprich et al., 2004). LRRK2 protein, also known as Dar-
darin, contains multiple functional domains and may function as
both an active GTPase and kinase (Li et al., 2007; West et al.,
2005). The most common mutation of LRRK2 is the G2019SNeuron 64, 807–827, December 24, 2009 ª2009 Elsevier Inc. 807
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kinase domain (Gilks et al., 2005; Nichols et al., 2005), which
may increase the putative LRRK2 kinase activity (West et al.,
2005). PD-related missense mutations are also found within
the GTPase domain of LRRK2 (Paisan-Ruiz et al., 2004; Zimprich
et al., 2004), which has been shown to physically interact with
both a- and b-tubulin and may regulate the dynamics of microtu-
bules in neurons (Gandhi et al., 2008; Gillardon, 2009). Although
mutant LRRK2 is toxic when overexpressed in cultured cells
(Greggio et al., 2006; Smith et al., 2006) and Drosophila (Imai
et al., 2008; Liu et al., 2008), no apparent neuronal loss is
observed in transgenic mice overexpressing PD-related LRRK2
R1441G and R144C mutants (Li et al., 2009; Tong et al., 2009).
The pathogenic mechanism of PD-related LRRK2 mutants
remains obscure.
To study the function of LRRK2 and how mutant LRRK2
causes neuron degeneration in vivo, we have generated LRRK2
knockout (LRRK2/) and transgenic mice expressing human
WT, G2019S, or kinase-domain-deletion (KD) LRRK2. Neither
deletion nor overexpression of LRRK2 caused any overt gross
neuropathological abnormalities in mutant mice. However,
coexpression of WT, G2019S, or KD LRRK2 with the PD-related
A53T a-syn caused synergistic toxicity to neurons that acceler-
ated the progression of a-syn-mediated neuropathology. Con-
versely, inhibition of LRRK2 expression reduced the aggregation
and somatic accumulation of a-syn, and delayed the progres-
sion of a-syn-mediated neuropathology. Our findings suggest
that LRRK2 may regulate A53T a-synuclein-mediated neuropa-
thology through modulating the intracellular trafficking and accu-
mulation of a-syn.
RESULTS
Generation of LRRK2 and a-synuclein Inducible
Transgenic Mice
As described previously (Wang et al., 2008), we have generated
LRRK2 inducible transgenic mice in which the expression of
C-terminal hemagglutinin (HA)-tagged human WT, G2019S, or
KD mutant LRRK2 was under the transcriptional control of tetra-
cycline operator (tetO) (Figure 1A). To make the KD expression
construct, we deleted residues from 1887 to 2102 of LRRK2,
resulting in a complete deletion of its kinase domain. In parallel
with the generation of LRRK2 inducible transgenic mice, we
also used the same strategy to generate new lines of human
a-syn A53T inducible transgenic mice (tetO-A53T). Given that
the expression pattern of LRRK2 (Galter et al., 2006) is similar
to that of calcium/calmodulin-dependent protein kinase II-alpha
(CaMKII) in the brain, we crossbred tetO-LRRK2 and tetO-
A53Tmice with a line ofCaMKII promoter-controlled tetracycline
transactivator (tTA) (CaMKII-tTA) mice (Mayford et al., 1996) to
achieve high-level expression of LRRK2 or a-syn in the forebrain
regions. Accordingly, our previous in situ hybridization experi-
ments showed that the expression of human LRRK2 was mainly
detected at the olfactory bulb, cerebral cortex, hippocampus,
and striatum in the brain of tetO-LRRK2 and CaMKII-tTA double
transgenic mice (Wang et al., 2008). For simplicity, we will later
refer to the tetO-LRRK2 WT/CaMKII-tTA, tetO-G2019S/CaM-
KII-tTA, and tetO-KD/CaMKII-tTA double transgenic mice as808 Neuron 64, 807–827, December 24, 2009 ª2009 Elsevier Inc.LRRK2WT, G2019S, and KD transgenic mice, respectively. We
refer to the E3 line as the G2019S transgenic mice and the C74
line as the LRRK2WT in later studies. Additionally, we designate
line C77 as the LRRK2 WT low expression line (LRRK2WT-L)
and line D10 as the KD mice.
We generated five independent lines of LRRK2WT, three inde-
pendent lines of G2019S, and three independent lines of KD
transgenic mice. In both G2019S and LRRK2WT mice, the
expression of LRRK2 protein was increased by about 8- to
16-fold compared with that in the endogenous one (Figures 1B
and S1B, available online). In the brain homogenate of KD
mice, a pair of LRRK2-positive bands was detected, the lower
of which likely represents the exogenous human LRRK2 with
truncated kinase domain (Figure 1B). The expression level of
exogenous human LRRK2 between LRRK2WT-L and KD trans-
genic mice was comparable, and was about 8- to 16-fold less
than that of LRRK2WT mice (Figure S1C). Therefore, the expres-
sion of LRRK2 was only modestly increased (<1-fold) in the brain
of LRRK2WT-L and KD mice as compared with that of nontrans-
genic (nTg) controls (Figure 1B). Q-RT-PCR was used to quantify
the expression of exogenous LRRK2 in the brain of LRRK2WT-L
and KD mice. The transcription of exogenous LRRK2 mRNA in
the brains of LRRK2WT-L and KD mice was about a 5- and
15-fold increase, respectively, over that in nTg controls (Fig-
ure S1D). The lower relative accumulation of exogenous
LRRK2 protein in the KDmouse brain likely reflects the instability
of this mutant protein.
Under the same transcriptional activation ofCaMKII promoter-
controlled tTA, the expression pattern of humana-syn in the brain
was the same as that of LRRK2 transgene (Figure 1C, upper
panel). Administration of doxycycline (DOX) suppressed the
expressionofexogenousa-syn in this ‘‘tet-off’’ system(Figure1C,
middle panel). The expression level of human A53T a-syn protein
was increased by about 30-fold as compared with that of endog-
enous protein (Figures 1D and S1B). Noticeably, under the
CaMKIIpromoter only a small fraction (<5%) of midbrain dopami-
nergic (DA) neurons expressed the transgene (Figures S1E–S1G).
Therefore, we focus our studies on the cortex and striatum, where
the exogenous a-syn and LRRK2 are widely expressed.
G2019S Inducible Transgenic Mice Developed Similar
Locomotor Abnormalities to Those of A53T Transgenic
Mice
All lines of LRRK2WT, G2019S, and KD transgenic mice were
viable and developed normally. G2019S mice appeared to gain
less body weight compared with nTg and tetO-G2019S single
transgenic mice starting at 12 months of age (Figure S2A, p <
0.0001). However, no significant difference in body weight was
found between G2019S and CaMKII-tTA mice (Figure S2A).
The motor functions of G2019S mice were examined by Rotarod
and Open-field tests. G2019S mice performed normally in the
Rotarod test (Figure S2C). However, they displayed significantly
increased ambulatory activities starting at 12 months of age
(Figure 1E, p < 0.05). G2019S mice also showed a trend
of increased rearing activities, but it did not reach statistical
significance (Figure 1G). In addition, there were no apparent
motor phenotypes detected in LRRK2WT mice up to 6 months
of age (Figures S2F–S2H). By contrast, A53T transgenic mice
Figure 1. Generation and Behavioral Char-
acterization of LRRK2 and a-syn Inducible
Transgenic Mice
(A) The schematic diagram shows the generation
of a-syn and LRRK2 inducible transgenic mice
using the ‘‘tet-off’’ system. (B) Western blot anal-
ysis shows LRRK2 expression in the brain of
nTg, LRRK2WT-L, LRRK2WT, G2019S, and KD
transgenic mice using a LRRK2 C-terminal anti-
body. Asterisks mark nonspecific bands. LRRK2
appeared as a double band in the KD sample.
(C) The expression pattern of A53T a-syn trans-
gene in the brain by in situ hybridization using
a P33-labeled human/mouse a-syn-specific oligo
probe (upper panel). The expression of transgenic
a-syn was suppressed by supplying the animals
with DOX-containing feed for 4 weeks (middle
panel). The endogenous a-syn was also highly
expressed by SNpc DA neurons (bottom panel).
Ob, olfactory bulb; Cx, cortex; St, Striatum; Hip,
hippocampus; SNpc, substantia nigra pars com-
pacta. (D) Western blots of a-syn expression in
the brain of nTg, tetO-A53T, and A53T transgenic
mice using an antibody recognizing both mouse
and human a-syn. (E and G) The nTg (n = 10),
tetO-G2019S (n = 10), CaMKII-tTA (n = 14), and
G2019S (n = 12) mice were subjected to Open-
field tests. The ambulatory (E) and rearing (G)
activities were quantified in the Open-field test.
*p < 0.05, #p < 0.005. (F and H) A53T transgenic
and control mice were subjected to the Open-field
test to evaluate their ambulatory (F) and rearing (H)
activities. n = 10 per genotype. *p < 0.05,
##p < 0.001.
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ure S2B, p < 0.0005), began to display drastic increases in ambu-
latory activities at 2 months of age (Figure 1F, p < 0.0001), and
displayed elevated rearing activities at 6 months of age (Fig-
ure 1H, p < 0.05). Together, the motor behavioral studies suggest
that overexpression of G2019S LRRK2 and A53T a-syn in the
forebrain regions may induce similar damages to the neural
circuitry responsible for regulating motor activities.
A53T Inducible Transgenic Mice Developed Progressive
Neuropathological Abnormalities Compared
with G2019S Transgenic Mice
To determine if any neuropathological abnormalities developed
in A53T and G2019S transgenic mice, we examined the brainNeuron 64, 807–827, Dsections of mutant and control animals
for neurodegeneration and associated
astrocytosis and microgliosis. The neuro-
degeneration was revealed by Jade C
and cleaved-caspase 3 (c-caspase 3)
staining. The presence of reactive astro-
cytes was examined by staining for glial
fibrillary acidic protein (GFAP). The
morphology of microglia was visualized
by staining for ionized calcium binding
adaptor molecule-1 (Iba1). Both Jade Cand c-caspase 3 stainings were negative in the brain sections
derived from 20-month-old G2019S transgenic mice (Figures
2Ad and 2Bd; Table 1). Consistently, stereological studies
revealed no significant changes in neuron counts at either the
frontal cortex or dorsal striatum between G2019S and age-
matched nTg mice (Figures 2E–2G). In addition, no apparent
increase in reactive astrocytosis or microglial activation was
observed in the striatum and cortex of G2019S transgenic
mice as compared with that of control nTg animals (Figure 2;
Tables 1 and 2). Similarly, no obvious gross neuropathological
phenotypes were found in 12-month-old LRRK2WT transgenic
mice (Table 1; Figures S2I–S2L).
No apparent neuropathological abnormalities were detected
in the striatum of 3-month-old A53T mice (Figures 2Aa–2Da),ecember 24, 2009 ª2009 Elsevier Inc. 809
Figure 2. A53T Transgenic Mice, but Not G2019S Transgenic Mice, Develop Progressive Neuropathology
(Aa–Ae) Representative images show Jade C staining (arrowheads) in the striatum of A53T mice at 3 (Aa), 12 (Ab), and 20 (Ac) months of age, and of G2019S (Ad)
and control nTg (Ae) mice at 20 months of age. Scale bar: 50 mm.
(Ba–Be) Representative images show c-caspase 3 (caspase3) staining (white arrowheads) in the striatum of A53T mice at 3 (Ba), 12 (Bb), and 20 (Bc) months of
age, and of G2019S (Bd) and control nTg (Be) mice at 20 months of age. Nuclei were stained with Topro 3 (blue). Scale bar: 50 mm.
(Ca–Ce) Representative images reveal GFAP staining (green) in the striatum of A53T mice at 3 (Ca), 12 (Cb), and 20 (Cc) months of age, and of G2019S (Cd) and
control nTg (Ce) mice at 20 months of age. The section was counterstained with an antibody against tyrosine hydroxylase (TH) (red). Scale bar: 100 mm.
(Da–De) Representative images show Iba1 staining (green) in the striatum of A53T mice at 3 (Da), 12 (Db), and 20 (Dc) months of age, and of G2019S (Dd) and
control nTg (De) mice at 20 months of age. Scale bar: 20 mm.
(E) Representative images display coronal sections costained with NeuN and TH across the striatum of 20-month-old nTg, CaMKII-tTA,G2019S, and A53T mice.
(F and G) Bar graphs depict the numbers of neurons remaining in the frontal cortex (F) and dorsal striatum (G) of 20-month-old nTg, CaMKII-tTA, G2019S, and
A53T mice. #p < 0.005 versus nTg.
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Table 1. Neuronal Degeneration in the Striatum and Cortex of A53T and LRRK2 Mutant Mice
# of c-caspase 3+ # of Jade C+
Age Genotype Striatum Cortex Striatum Cortex
1 month nTg 0 0 0 0
tTA 0 0 0 0
A53T 0 0 0 0
LRRK2WT-L 0 0 0 0
LRRK2WT 0 0 0 0
KD 0 0 0 0
G2019S 0 0 0 0
A53T/LRRK2WT-L 1.4 ± 0.2 2.4 ± 0.2 3.4 ± 0.5 5.2 ± 0.5###
A53T/LRRK2WT 3.0 ± 0.7 8.0 ± 1.1 12.0 ± 0.9** 15.8 ± 1.1**
A53T/G2019S 13.0 ± 1.5**,*** 17.3 ± 0.3 26.0 ± 1.2** 28.7 ± 1.9**
A53T/KD 1.3 ± 0.3 3.0 ± 0.1 2.7 ± 0.3 8.0 ± 1.3##
12 months nTg (DOX) 0 0 0 0
A53T 5.0 ± 0.6 6.3 ± 0.5 12.0 ± 0.6 13.3 ± 1.5
A53T/LRRK2/ 0 0 0 0
A53T/DOX 0 0 0 0
LRRK2WT 0 0 0 0
20 months nTg0 0 0 0 0
A53T 24.7 ± 4.1 32 ± 4.4 33.3 ± 4.1 40.3 ± 4.3
G2019S 0 0 0 0
LRRK2/ 0 0 0 0
The average numbers of c-caspase-3-positive and Jade C-positive cells in the striatum and cortex of each cohort of mice were counted by the event
measurement tool of AxioVision (Zeiss). Two matched sections were analyzed for each mouse and three or more animals per genotype were used for
each age group. The randomly selected sampling area was140,000 mm2 per brain region for each animal. nTg0 represents nTg mice from both trans-
genic and LRRK2/ cohorts of mice. At 1 month of age, significantly more c-caspase-3-positive (c-caspase 3+) neurons were revealed in the striatum
and cortex of A53T/G2019S mice as compared to the numbers in A53Tmice (**p < 0.0005) and A53T/LRRK2WTmice (***p < 0.005). Additionally, more
Jade C-positive (Jade C+) cells were found in the striatum and cortex of A53T/LRRK2WT-L, A53T/LRRK2WT, A53T/KD, and A53T/G2019S mice as
compared to numbers in A53T mice (**p < 0.0005; ##p < 0.01; ###p < 0.05). More Jade C-positive cells were also detected in the striatum and cortex of
A53T/G2019S mice relative to numbers in A53T/LRRK2WT mice (**p < 0.0005).
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mice were examined at 12 and 20 months of age (Figure 2;
Tables 1 and 2), and widespread neurodegeneration was evident
in the brains of 20-month-old A53T transgenic mice (Figures
2Ac–2Bc and 2E). Massive neuronal loss in the frontal cortex
(>80%) and dorsal striatum (>74%) of A53T mice was estimated
by unbiased stereological approaches (Figures 2F and 2G).
Therefore, A53T mice developed age-dependent, progressive
neurodegeneration, whereas G2019S mice did not show any
obvious gross neuropathological phenotypes.
LRRK2 Accelerated the Progression of A53T
a-syn-Mediated Neuropathology
To test whether overexpression of LRRK2 affects A53T a-syn-
mediated neurodegeneration, we generated A53T/LRRK2WT-
L, A53T/LRRK2WT, A53T/G2019S, and A53T/KD double trans-
genic mice and examined the progression of neuropathological
alterations (Figure 3). Compared to 1-month-old A53T single
transgenic mice, the number of GFAP-positive astrocytes was
significantly elevated in the striatum of age-matched A53T/
LRRK2WT-L and A53T/LRRK2WT double transgenic mice (Fig-
ures 3A and 3E). In addition, more GFAP-positive astrocyteswere found in the brain of A53T/LRRK2WT mice than A53T/
LRRK2WT-L mice (Figures 3A and 3E), suggesting that the
expression level of LRRK2 influences the progression of a-syn-
mediated neuropathology. A similar increase of microglial
activation was also observed in A53T/LRRK2WT-L and A53T/
LRRK2WT double transgenic mice (Figures 3B; Table 2). In addi-
tion to gliosis, neurodegeneration was also accelerated in the
striatum of A53T/LRRK2WT-L and A53T/LRRK2WT transgenic
mice (Figure 3; Table 1). Costaining of c-caspase 3 with Ctip2,
a specific marker for striatal medium-size spiny neurons (MSN)
(Arlotta et al., 2008), revealed that most of these degenerating
neurons were MSNs (Figure S3). The prevalence of neurodegen-
eration in A53T/LRRK2WT double transgenic mice was also
elevated in a LRRK2 dose-dependent fashion (Figure 3F;
Table 1). Taken together, these findings demonstrate that over-
expression of LRRK2 accelerates the progression of a-syn-
mediated neuropathology.
Since the G2019S mutation in LRRK2 causes late-onset PD,
we decided to investigate whether the G2019S mutation would
further enhance the neuropathology in A53T/G2019S mice
as compared with that in A53T/LRRK2WT double transgenic
mice. A significant exacerbation of astrocytosis, microgliosis,Neuron 64, 807–827, December 24, 2009 ª2009 Elsevier Inc. 811
Table 2. Activation of Microglia in the Striatum of A53T and
LRRK2Mutant Mice
Age Genotype Ratio (%) Size (mm2)
1 month nTg 0 31.77 ± 0.46
tTA 0 28.95 ± 1.63
A53T 0 36.83 ± 0.86
G2019S 0 31.69 ± 0.76
A53T/LRRK2WT-L 5.88 44.40 ± 3.73
A53T/LRRK2WT 31.64 52.01 ± 1.60*
A53T/G2019S 83.10 79.55 ± 7.01**
A53T/KD 11.11 46.66 ± 0.05
12 months nTg (DOX) 0 38.52 ± 0.01***
A53T 38.71 60.97 ± 2.46
A53T/LRRK2-/- 0 29.93 ± 2.90#
A53T/DOX 0 36.91 ± 0.06***
20 months nTg0 0 31.44 ± 1.17
A53T 79.63 102.07 ± 10.88##,###
G2019S 0 33.33 ± 0.63
LRRK2/ 11.11 45.00 ± 2.32###
The numbers of total and activated Iba1-positive cells in the striatum
were counted by the event measurement tool of AxioVision. The ratio of
activated Iba1-positive cells was calculated by dividing the number of
enlarged Iba1-positive cells by the total number of Iba1-positive cells.
The sizes of Iba1-positive cell bodies were assessed by the outline func-
tion of AxioVision. Two matched sections were analyzed for each mouse
and three or more animals per genotype were used for each age group.
The area of sampled striatum was 140,000 mm2 for each animal. At
1 month of age, enlarged Iba1-positive cells were only detected in
A53T and LRRK2 double transgenic mice. While the average size of
Iba1-positive cell bodies appears larger inA53T and LRRK2 double trans-
genic mice, it reached statistical significance in onlyA53T/LRRK2WT and
A53T/G2019S mice as compared with A53T mice (*p < 0.02; **p <
0.0005). At 12 months of age, more enlarged Iba1-positive cells were de-
tected inA53Twith increasing size of cell bodies. In contrast, no apparent
enlargement of Iba1-positive cells was found in nTg, A53T/LRKK2/, or
A53T/DOX mice as compared to A53T mice (***p < 0.005; #p < 0.002). At
20 months of age, more and larger enlarged Iba1-positive cells were
found in A53T mice as compared to amounts in nTg and G2019S mice
(##p < 0.01) and 12-month-old A53T mice (###p < 0.05). Interestingly,
more enlarged Iba1-positive cells were detected in LRRK2/ mice as
compared to nTg mice (###p < 0.05). nTg0 represents nTg mice from
both transgenic and LRRK2/ cohorts of mice.
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G2019Smice as compared with age-matchedA53T single trans-
genic animals (Figure 3; Tables 1 and 2). When we compared the
pathological phenotypes of 1-month-old A53T/LRRK2WT and
A53T/G2019S mice, we found that the numbers of Jade-C-posi-
tive and GFAP-positive cells, and the activation levels of micro-
glia, were significantly increased in the striatum of A53T/G2019S
mice as compared with those of A53T/LRRK2WT animals
(p < 0.0001, p < 0.005, and p < 0.002, for Jade C-positive cells,
GFAP-positive cells, and microglial activation, respectively;
Figure 3E; Tables 1 and 2). However, when we compared the
numbers of neurons remaining in the striatum ofA53T/LRRK2WT
and A53T/G2019S mice, the difference was not statistically
significant (p = 0.14, Figure 3F). To further investigate whether812 Neuron 64, 807–827, December 24, 2009 ª2009 Elsevier Inc.the kinase domain of LRRK2 is critical in regulating a-syn
A53T-mediated neuropathology, we compared the progression
of neuropathology between A53T/KD and A53T/LRRK2WT-L
transgenic mice. As shown in Figure 3, the presence of KD
LRRK2 also accelerated A53T-mediated neuropathology to
a similar extent as LRRK2WT-L (Figure 3; Tables 1 and 2). These
data suggest that the kinase domain of LRRK2 perhaps is not
critical in modulating A53T-induced neuropathological abnor-
malities.
We further examined the neurodegeneration of A53T, A53T/
LRRK2WT, and A53T/G2019S mice at 6 months of age (Figures
3G and 3H). While no obvious neuronal loss was observed
in either LRRK2WT or G2019S mice, a significant reduction
(30%) of striatal neurons was found in A53T single transgenic
mice (Figures 3G and 3H, p < 0.02). More dramatic neuronal
loss was detected in the dorsal striatum of A53T/LRRK2WT
and A53T/G2019S mice (80% and 85%, respectively; Figures
3G and 3H, p < 0.001 and 0.0001). However, the numbers of
residual neurons in the dorsal striatum of A53T/LRRK2WT and
A53T/G2019S mice were not statistically different (p = 0.45,
Figure 3H). These observations from adult mice further sup-
port our earlier findings that the presence of excess WT and
G2019S LRRK2 exacerbates A53T-mediated neurodegenera-
tion, and that the expression level of LRRK2, rather than the
PD-related G2019S mutation, is perhaps more important in
accelerating A53T a-syn-mediated pathogenesis.
Wondering whether overexpression of any exogenous pro-
tein could accelerate a-syn-mediated neuropathology, we
crossbred A53T mice with a line of green fluorescent protein
(GFP) transgenic mice that selectively express GFP in striatal
neurons (Gong et al., 2003). We did not observe any significant
influence of GFP on the progression of neuropathology in
A53T/GFP double transgenic mice (Figures 3E and S4). In addi-
tion, to test if LRRK2 selectively potentiates A53T-mediated
neuropathology, we crossbred G2019S mice with amyloid
precursor protein (APP) inducible transgenic mice in which
an Alzheimer’s disease-related double mutant version of chi-
meric mouse/human APP is overexpressed 10- to 30-fold
compared with the endogenous APP (Jankowsky et al.,
2005). We found that LRRK2 did not accelerate APP-mediated
astrocytosis and microgliosis in APP/G2019S double trans-
genic mice (Figure S5). Together, these observations support
a specific effect of LRRK2 on the pathogenesis of a-syn A53T
mutation.
LRRK2 Promoted the Abnormal Accumulation
of a-syn in Cell Bodies
The a-syn staining is normally confined to axon terminals
(Maroteaux et al., 1988), a pattern shown here as small puncta
in the coronal striatal sections of 3-month-old A53T mice and
20-month-old nTg mice (Figure 4). Interestingly, a few neurons
with strong a-syn staining in the cell body were detected in the
brain sections of 12-month-old A53T mice (Figures 4B and 4F).
The occurrence of this abnormal somatic accumulation of a-syn
was more prominent in the brain sections of 20-month-old
A53T mice (Figures 4C and 4G; Table 3), which was closely
correlated with the progression of neurodegeneration in A53T
mice, suggesting that the somatic accumulation of a-syn may
Neuron
LRRK2 and a-synuclein Double Transgenic Micetrigger the pathogenic cascades leading to cell death. We then
investigated whether overexpression of LRRK2 affects the sub-
cellular distribution of a-syn. No obvious a-syn staining was
found in the cell body of striatal neurons in 1-month-old A53T
mice (Figure 4I). However, coexpression of LRRK2 G2019S
mutation greatly promoted the accumulation of a-syn in the
soma of A53T/G2019S neurons in 1-month-old mice (Figures
4J–4L; Table 3). Similarly, increasing numbers of neurons with
somatic accumulation of a-syn were detected in brain sec-
tions of 1-month-old A53T/LRRK2WT-L, A53T/LRRK2WT, and
A53T/KD transgenic mice in a LRRK2 dose-dependent manner
(Figures 4M–4P; Table 3). To investigate whether overexpression
of LRRK2 G2019S mutation also promotes the accumulation of
WT a-syn in the cell bodies, we examined the a-syn staining in
brain sections from 20-month-old G2019S mice and 1-month-
old human a-syn WT and G2019S double transgenic mice
(a-synWT/G2019S). No apparent a-syn staining was detected
in the soma of neurons in G2019S and a-synWT single trans-
genic mice (Figure S6). By contrast, somatic staining of a-syn
was apparent in neurons of 1-month-old a-synWT/G2019S
double transgenic mice (Figure S6). These results suggest that
the LRRK2-induced somatic accumulation of a-syn is indepen-
dent of the presence of PD-related a-syn mutation but relies
on the expression level of a-syn.
The staining of LRRK2 seemed to partially overlap with that of
a-syn in the soma (Figures 4L and 4P). However, coimmunopre-
cipitation experiments failed to pull down LRRK2 and a-syn
together from brain homogenates of A53T/G2019S and A53T/
LRRK2WT mice (X.-L.G., unpublished data). In addition, a few
neurons, which showed obvious a-syn staining in the soma,
lacked substantial expression of LRRK2 transgene (asterisk,
Figures 4L and 4P). These observations suggest that LRRK2
may not directly bind to a-syn and prevent its trafficking to the
axon terminals.
LRRK2 Promoted the Formation of a-syn Aggregates
To examine if increased somatic accumulation of a-syn corre-
lates with the formation of a-syn aggregates, we compared the
levels of a-syn protein in total and sequentially detergent-
extracted fractions of brain homogenates from 1- and 12-month-
old A53T transgenic mice. The formation of a-syn aggregates
was detected as a-syn-positive high molecular weight (HMW)
bands in the total brain homogenates of A53T mice (Figure 5).
Interestingly, the intensity of HMW bands was significantly
enhanced in the samples of 12-month-old A53T mice as com-
pared with those of 1-month-old animals (Figure 5A). We then
examined the presence of a-syn aggregates in the Triton
X-100-insoluble (TX-insol) fractions of brain extracts. While the
level of TX-sol a-syn was comparable between these two age
groups, a significant increase in TX-insol HMW a-syn was found
in the samples of 12-month-old A53T mice (Figure 5B). These
data indicate that the accumulation of a-syn in the soma may
favor the formation of a-syn aggregates or vice versa.
Since overexpression of LRRK2 promoted the somatic accu-
mulation of a-syn, we reasoned that LRRK2 may also promote
the aggregation of a-syn. We therefore compared the level
of HMW a-syn in the total brain lysates of 1-month-old A53T
and age-matched A53T/G2019S transgenic mice. A modestincrease of HMW a-syn was detected in the A53T/G2019S
samples (Figure 5C). Similarly, significantly more a-syn was
detected in the TX-insol fraction of brain homogenates from
A53T/G2019S transgenic mice (Figures 5D and 5E, p = 0.033).
Together, these observations indicate that G2019S LRRK2
promotes the formation of a-syn aggregates in neurons.
To test if a-syn is a potential substrate of LRRK2’s kinase
activity, we examined the phosphorylation of a-syn in total
brain homogenates derived from 1-month-old A53T and A53T/
G2019S transgenic mice (Figures 5D and 5E). Unexpectedly,
we observed a reduction of a-syn phosphorylation at serine
129 in the brain lysate of double transgenic mice as compared
with that in A53T single transgenic animals (p = 0.001). This
observation indicates that a-syn is unlikely to be a physiological
substrate of LRRK2’s kinase activity in vivo. Secreted a-syn is
also implied in the pathogenesis of PD (Lee et al., 2005). To
investigate if LRRK2 affects the secretion of a-syn, we measured
the level of a-syn in cerebral spinal fluid (CSF) by ELISA. We
found no significant alteration of secreted a-syn in A53T/
G2019S double transgenic mice as compared to that in A53T
single transgenic mice (data not shown).
Coexpression of LRRK2 and A53T Led to Severe
Fragmentation of Golgi Complex in Neurons
Recent studies indicate that overexpression of either WT or
PD-related mutant a-syn disrupts ER-Golgi traffic and causes
Golgi fragmentation (Cooper et al., 2006; Gosavi et al., 2002).
Interestingly, LRRK2 is associated with the Golgi apparatus
(Biskup et al., 2006). We therefore decided to examine the ER
and Golgi structures in neurons of A53T and LRRK2 single and
double transgenic mice. There was no apparent change of ER
structure in these neurons as revealed by calnexin staining
(data not shown). However, the structure of Golgi complex
was drastically altered in neurons of 1-month-old A53T/LRRK2
double transgenic mice (Figure 6). The morphology of the Golgi
apparatus was examined by GM130 and GLG1 staining, which
recognize cis and medial/trans-Golgi apparatus, respectively.
GM130 staining revealed tubular structures largely stacked at
one side of neurons in 1-month-old nTg and A53T mice (arrows,
Figures 6A and 6D), which were classified as ‘‘Normal’’ Golgi.
The GM130-positive tubules, however, appeared thinner and
fragmented in neurons of LRRK2WT and G2019S mice (Figures
6B and 6C). When A53T was coexpressed with either WT or
G2019S LRRK2, severe fragmentation of cis-Golgi was found
(asterisk, Figures 6E and 6F), which was designed as ‘‘Frag-
mented’’ Golgi thereafter, with the partially fragmented Golgi
referred to as ‘‘Intermediate’’ Golgi. Interestingly, the degree of
Golgi apparatus fragmentation was correlated with the somatic
accumulation of a-syn in these neurons (asterisks, Figures 6H
and 6I). By contrast, neurons that lacked substantial a-syn stain-
ing in the soma displayed a fairly normal-appearing cis-Golgi
network (arrows, Figures 6E, 6F, 6H, and 6I). The prevalence of
cis-Golgi fragmentation was quantified, a significant decrease
of Normal Golgi in LRRK2 single and A53T/LRRK2 double
transgenic neurons as compared with amounts in nTg controls
was observed (Figure 6P). Meanwhile, the ratio of Fragmented
Golgi was significantly elevated in neurons of A53T/LRRK2
double transgenic mice (Figure 6P). We also examined theNeuron 64, 807–827, December 24, 2009 ª2009 Elsevier Inc. 813
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animals and observed a similar fragmentation of GM130-pos-
itive Golgi apparatus in LRRK2WT, G2019S, and A53T/LRRK2
double transgenic neurons (Figure S7). Interestingly, a significant
increase in Golgi fragmentation was observed in neurons of
6-month-old A53T mice (Figure S7).
We then checked the structural integrity of medial/trans-Golgi
in neurons of A53T and LRRK2 mutant mice. In control nTg
mice, GLG1 staining revealed the Normal perinuclear and polar-
ized localization of Golgi stacks in neurons (arrows, Figure 6J).
However, GLG1 staining was significantly altered in LRRK2WT,
G2019, and A53T neurons and illuminated tubular structures
scattered around the nucleus (arrowheads, Figures 6K–6M). In
A53T/LRRK2WT and A53T/G2019S neurons, with a few excep-
tions (arrowheads, Figures 6N and 6O), the GLG1 staining was
dispersed as small puncta or became indistinguishable from
the background staining (asterisks, Figures 6N and 6O). We
classified these dispersed structures as Fragmented Golgi.
The ratio of Fragmented trans-Golgi was calculated, which
was significantly increased in A53T and LRRK2 single and
double transgenic neurons as compared with that of nTg con-
trols (Figure 6Q). Increased fragmentation of the Golgi apparatus
was also observed in neurons of KD and A53T/KD mice (Fig-
ures 6P and 6Q). Together these observations demonstrate
that overexpression of LRRK2 and a-syn severely disrupted
the structure of the Golgi apparatus, which may impair the
ER-Golgi trafficking and contribute to the somatic accumulation
of a-syn.Overexpression of LRRK2 Perturbed the Dynamics
of Microtubule Assembly in LRRK2 and A53T/LRRK2
Transgenic Mice
Microtubule and microtubule-based intracellular transport play
critical roles in maintaining the structure and function of the Golgi
apparatus (Thyberg and Moskalewski, 1999). LRRK2 has been
shown to physically interact with both a- and b-tubulin through
its GTPase domain (Gandhi et al., 2008; Gillardon, 2009). Consis-
tently, we found that both WT and G2019S LRRK2 costained
with bIII-tubulin in the soma and proximal processes of striatal
neurons in 1- and 6-month-old LRRK2 single and A53T/LRRK2
double transgenic mice (Figures 7 and S8). A significant overlap
of somatic a-syn and bIII-tubulin staining was also observed inFigure 3. LRRK2 Accelerates the Progression of A53 a-syn-Mediated N
(Aa–Ae) Representative images show GFAP staining in the striatum of 1-month-ol
and A53T/KD (Ae) mice. Scale bar: 100 mm.
(Ba–Be) Representative images show Iba1 staining in the striatum of 1-month-old
and A53T/KD (Be) mice. Scale bar: 50 mm.
(Ca–Ce) Representative images show Jade C staining in the striatum of 1-month
(Cd), and A53T/KD (Ce) mice. Scale bar: 20 mm.
(Da–De) Representative images show c-caspase 3 staining in the striatum of 1
G2019S (Dd), and A53T/KD (De) mice. Scale bar: 50 mm.
(E and F) Bar graphs reveal the numbers of GFAP-positive (GFAP+, E) and NeuN
methods. *p < 0.05, ##p < 0.001.
(G) Representative images show coronal sections across the striatum of 6-month
with NeuN and TH.
(H) Bar graph depicts the numbers of neurons remaining in the dorsal striatum (G
G2019S mice. *p < 0.05, #p < 0.005, ##p < 0.001.neurons of 6-month-old A53T single transgenic mice (Figure S8),
as well as in neurons of 1- and 6-month-old A53T/LRRK2WT and
A53T/G2019S double transgenic mice (Figures 7Dc, 7Dd, and
S8). These observations were consistent with the previous report
that prefibrillar cytoplasmic a-syn interacts with tubulin in cell
cultures (Lee et al., 2006).
To reveal the functional impact of LRRK2 overexpression on
the dynamics of microtubule organization, we compared the
level of b-tubulin in both the Reassembly High-salt Buffer (RAB)-
soluble (RAB-S) and insoluble fractions of mouse brain homoge-
nates from 1-month-old A53T, LRRK2WT, and G2019S single
mutant animals; A53T/LRRK2 double transgenic animals; and
nTg controls (Figures 7G–7I). RAB buffer is generally used to
extract intracellular free tubulin and cold-labile microtubules
from brain homogenates (Weingarten et al., 1975). A dramatic
reduction of b-tubulin was observed in the RAB-S fraction of
brain homogenates in LRRK2WT, G2019S, and A53T/LRRK2
transgenic mice as compared with those of nTg controls and
A53T single transgenic mice (Figures 7G and 7H). Concomi-
tantly, more b-tubulin was found in the RAB-insoluble pellets
(RAB-P) of LRRK2-overexpressing mouse brains than those
from nTg and A53T samples (Figures 7G and 7I). The total level
of b-tubulin, meanwhile, was comparable among all different
genotypes (Figure S9). The distribution of a-tubulin followed
the same pattern as b-tubulin in the RAB-extracted brain homog-
enates from LRRK2 transgenic mice (data not shown). Taken
together, these findings are consistent with previous in vitro
assays showing that overexpression of LRRK2 may enhance
the polymerization of tubulin in cells (Gillardon, 2009), ultimately
suggesting that the impairment of microtubule assembly may
affect the organization of microtubule network in the cell, result-
ing in the fragmentation of the Golgi apparatus.Overexpression of LRRK2 and A53T Impaired
Ubiquitin-Proteasome System in Both A53T and LRRK2
Transgenic Mice
a-syn aggregates have been shown previously to impair the pro-
teasomal and lysosomal activities that lead to accumulation of
ubiquinated proteins in cells (Cuervo et al., 2004; Tanaka et al.,
2001). Consistently, an elevation of ubiquitin (Ubi) staining was
observed in the soma and nucleus of cortical neurons from
6-month-old A53T mice (arrows, Figure 8Aa), but not from thoseeuropathology
d A53T (Aa), A53T/LRRK2WT-L (Ab), A53T/LRRK2WT (Ac), A53T/G2019S (Ad),
A53T (Ba), A53T/LRRK2WT-L (Bb), A53T/LRRK2WT (Bc), A53T/G2019S (Bd),
-old A53T (Ca), A53T/LRRK2WT-L (Cb), A53T/LRRK2WT (Cc), A53T/G2019S
-month-old A53T (Da), A53T/LRRK2WT-L (Db), A53T/LRRK2WT (Dc), A53T/
-positive cells (F) in the dorsal striatum estimated by unbiased stereological
-old nTg, A53T, G2019S, and A53T/G2019S mice. The section was costained
) of 6-month-old nTg, A53T, LRRK2WT, G2019S, A53T/LRRK2WT, and A53T/
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Figure 4. LRRK2 Accelerates Somatic Accumulation of A53T a-syn in Neurons
(A–H) Representative images show a-syn staining (green) in striatal neurons of A53T mice at 3 (A), 12 (B), and 20 months of age (C), and of nTg mice at 20 months
of age (D). (F) and (G) represent enlarged areas demarcated by the white boxes in (B) and (C), respectively. Nuclei were stained with Topro 3 (blue). Scale bars:
50 mm (A–D); 10 mm (E–H).
(I–P) Representative images reveal a-syn staining (green) in striatal neurons of 1-month-old A53T (I), A53T/G2019S (J and L), A53T/LRRK2WT-L (M), and A53T/
LRRK2WT (N and P) mice. Human LRRK2 was stained with an anti-HA antibody (red; K, L, O, and P). Nuclei were stained with Topro 3 (blue). Scale bar: 10 mm.
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LRRK2 and a-synuclein Double Transgenic Miceof nTg controls (Figure 8Ae). The Ubi staining was partially over-
lapped with a-syn (Figure 8Ca). The pattern of Ubi staining was
altered in 20-month-old A53T mice, which displayed a punctu-
ated staining pattern at neuron processes with no apparent
colocalization with a-syn staining (arrowheads, Figures 8Ab
and 8Cb). In the presence of excess WT LRRK2, slightly more
a-syn and Ubi-positive clusters were observed in brain sections816 Neuron 64, 807–827, December 24, 2009 ª2009 Elsevier Inc.of 6-month-old A53T/LRRK2WT mice (arrowheads, Figure 8Bc).
Interestingly, the presence of G2019S seemed to shift the Ubi
staining pattern to a more perinuclear location in neurons of
A53T/G2019S mice (arrow, Figure 8Ad).
We then examined the Ubi staining in LRRK2 transgenic mice.
The level of Ubi staining was increased in cortical neurons
of 6-month-old LRRK2WT and G2019S mice (Figure 8D).
Table 3. The Prevalence of Somatic Accumulation of a-syn in the
Striatal Neurons of A53T Transgenic Mice

















The ratio of striatal neurons displaying apparent somatic accumulation of
a-syn was calculated from each cohort of mice. Two matched sections
were analyzed for each mouse and three or more animals per genotype
were used for each age group. The area of sampled striatum was
140,000 mm2 for each animal. nTg0 represents nTg mice from both
transgenic and LRRK2/ cohorts of mice. At 1 month of age, signifi-
cantly more neurons with apparent somatic accumulation of a-syn
were detected in the striatum of A53T/LRRK2WT, A53T/G2019S, and
A53T/KD mice as compared to A53T mice (*p < 0.02; **p < 0.0005; and
#p < 0.001). At 12 months of age, fewer neurons with somatic accumula-
tion of a-syn were found in the striatum of A53T/LRKK2/ and A53T/
DOX mice as compared to those in A53T mice (*p < 0.02; ###p < 0.05).
Figure 5. LRRK2 Promotes the Formation of a-syn Aggregates
(A and B) Western blots show high molecular weight (HMW) bands of a-syn in
the total (A) and sequentially detergent-extracted (B) brain homogenates of
A53T transgenic mice at 1 and 12 months of age. The middle panel in (A) shows
the monomeric a-syn (a-syn mono) under lower exposure.
(C) Western blots show a-syn-positive HMW bands in the total brain homoge-
nates of A53T single and A53T/G2019S double transgenic mice at 1 month
of age. The middle panel in (C) shows the monomeric a-syn with shorter
exposure.
(D) Western blots show phosphorylated a-syn (pa-syn) in the total fractions
and monomeric a-syn in sequentially detergent-extracted fractions of brain
homogenates of A53T single and A53T/G2019S double transgenic mice at
1 month of age.
(E) Bar graph comparing the levels of a-syn and pa-syn in different fractions of
brain homogenates of A53T and A53T/G2019S transgenic mice at 1 month of
age. *p < 0.05, **p < 0.01.
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LRRK2 and a-synuclein Double Transgenic MiceInterestingly, the occurrence of Ubi-positive clusters was more
prominent in G2019S neurons (arrowheads, Figure 8D). These
Ubi-positive clusters appeared costained with LRRK2 in
G2019S neurons (arrowheads, Figure 8F). This phenomenon
became more apparent in neurons of 20-month-old G2019S
mice in which LRRK2 and Ubi staining were tightly colocalized
as clusters (arrowheads, Figure 8Fe). Moreover, the presence
of A53T a-syn accelerated the clustering of LRRK2 staining in
neurons of A53T/G2019S mice (arrowheads, Figures 8Ed and
8Fd) as compared with that in age-matched G2019S mice
(Figures 8Dc and 8Fc). In contrast, no obvious LRRK2-positive
clusters were found in neurons of 6-month-old LRRK2WT and
A53T/LRRK2WT mice (Figures 8Da, 8Db, 8Fa, and 8Fb). Taken
together, these observations indicate that G2019S LRRK2 may
further inhibit ubiquitin-proteasome system (UPS) activities,
resulting in more frequent formation of LRRK2 and Ubi-positive
aggregates in neurons of aged G2019S mice (Figures 8De and
8Ee). Our studies also indicate that the presence of A53T a-syn
and G2019S LRRK2 may cause synergistic impairment of UPS
activities, which further accelerates the formation of LRRK2/
Ubi-positive aggregates in neurons of A53T/G2019S double
transgenic mice (Figures 8Dd and 8Ed).
In parallel with immunohistological studies, we also checked
the levels of ubiquitinated proteins in brain homogenatesNeuron 64, 807–827, December 24, 2009 ª2009 Elsevier Inc. 817
Figure 6. a-syn and LRRK2 Cause Synergistic Damage to the Golgi Apparatus
(A–I) Representative images show GM130 staining (arrows, green) in the striatum of nTg (A), LRRK2WT (B),G2019S (C),A53T (D and G),A53T/LRRK2WT (E and H),
and A53T/G2019S (F and I) mice at 1 month of age. Costaining of GM130 (green) and a-syn (red) was shown in the striatum of A53T (G), A53T/LRRK2WT (H), and
A53T/G2019S (I) mice. Neurons displaying somatic accumulation of a-syn are marked with asterisks. Normal GM130 staining in neurons is indicated by arrows.
Nuclei were labeled by Topro 3 staining (blue). Scale bar: 10 mm.
(J–O) Representative images show GLG1 staining (green) in the striatum of nTg (J), LRRK2WT (K), G2019S (L), A53T (M), A53T/LRRK2WT (N), and A53T/G2019S
(O) mice at 1 month of age. Normal GLG1 staining in neurons is indicated by arrows, and abnormal tubular and fragmented GLG1 staining is marked by arrow-
heads. Neurons with complete fragmentation of Golgi are marked with an asterisk. Nuclei were labeled by Topro 3 staining (blue). Scale bar: 10 mm.
(P and Q) Bar graphs quantify the morphological changes of cis- (P) and trans- (Q) Golgi in neurons (>300 neurons and R3 mice per genotype). *p < 0.05,
#p < 0.0005.
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LRRK2 and a-synuclein Double Transgenic Miceof A53T, LRRK2WT, G2019S, A53T/LRRK2WT, and A53T/
G2019S mice by western blots (Figure 8G). A significant eleva-
tion of ubiquitination was observed in the brain homogenates
of 3-month-old A53T and A53T/LRRK2WT mice as compared
with that of age-matched nTg, LRRK2WT, and G2019S mice
(Figure 8H). The level of ubiquitination, however, was only mod-
erately increased in the brain samples of 18-month-old G2019S
mice as compared with that of age-matched nTg controls
(Figures 8G and 8H).818 Neuron 64, 807–827, December 24, 2009 ª2009 Elsevier Inc.LRRK2 Exacerbated Mitochondrial Structural
and Functional Abnormalities in Neurons of A53T
Transgenic Mice
Mitochondrial dysfunction has been shown in cell and mouse
models overexpressing PD-related mutant a-syn (Hsu et al.,
2000; Martin et al., 2006). We examined the morphology of mito-
chondria in striatal neurons of 1-month-old mice by EM and
found distinctive structural changes in some of the mitochondria
in A53T and A53T/G2019S neurons. Compared with nTg and
Figure 7. Overexpression of LRRK2 Impairs the Dynamics of Microtubules
(A–C) Representative images show bIII-tubulin (green) and HA (red) staining in the striatum of LRRK2WT (Aa, Ba, and Ca), G2019S (Ab, Bb, and Cb), A53T/
LRRK2WT (Ac, Bc, and Cc), and A53T/G2019S (Ad, Bd, and Cd) mice at 1 month of age. Nuclei were labeled by Topro 3 staining (blue). Scale bar: 10 mm.
(D–F) Representative images show bIII-tubulin (green) and a-syn (red) staining in the striatum of nTg (Da, Ea, and Fa), A53T (Db, Eb, and Fb), A53T/LRRK2WT
(Dc, Ec, and Fc), and A53T/G2019S (Dd, Ed, and Fd) mice at 1 month of age. The abnormal somatic accumulation of a-syn and bIII-tubulin is marked by arrow-
heads. Nuclei were labeled by Topro 3 staining (blue). Scale bar: 10 mm.
(G) Western blots of b-tubulin in RAB-S and RAB-P fractions of brain homogenates from various transgenic mice at 1 month of age and age-matched nTg
controls.
(H and I) Bar graphs quantify the levels of b-tubulin in RAB-S (H) and RAB-P (I) fractions of brain homogenates of transgenic mice at 1 month of age and age-
matched nTg controls. *p < 0.05, ##p < 0.001.
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LRRK2 and a-synuclein Double Transgenic MiceG2019S samples, the matrix of these abnormal mitochondria
was denser (large arrows in Figures 9C, 9D, 9G, and 9H), and
the cristae became widened (small arrows in Figure 9G). The
frequency of such abnormal mitochondria was 52/1000 mm2 in
striatal area of A53T mice and 3.5 times higher in A53T/
G2019S double transgenic mice (184/1000 mm2), whereas virtu-
ally no abnormal mitochindria were found in age-matched nTg or
G2019S transgenic mice (Figures 9A–9D). The abnormal mito-
chondria were preferentially distributed in dendrites/soma, with
only a few in axon terminals (J.-H.T.-C., unpublished data). The
mitochondrial structural abnormalities were also confirmed by
immunostaining with an antibody against cytochrome c oxidase
subunit I, a mitochondrial inner membrane protein (Figure S10).
To address whether the morphological abnormalities affect
the function of mitochondria in striatal neurons of 1-month-old
A53T and A53T/G2019S transgenic mice, we infused the animal
with MitoSox Red, a fluorescent dye for detecting the surplus of
mitochondrial superoxide released to the matrix (Robinson et al.,
2006). MitoSox Red signal was easily detected in the brain of
A53T/G2019S transgenic mice and was more prominent in the
dorsal lateral striatum (Figures 9L and 9M), where most neurode-
generation was found. In contrast, only a few MitoSox-Red-posi-
tive neurons were found in the stratum of A53T mice (arrowhead,
Figure 9K) and no positive staining was detected in nTg or
G2019S transgenic mice (Figures 9I and 9J). These results
suggest that coexpression of a-syn and LRRK2 cause syner-
gistic toxicity to mitochondria.Inhibition of LRRK2 Expression Ameliorated
a-syn-Mediated Neuropathology
Since overexpression of LRRK2 accelerated the progression of
a-syn-induced neuropathological abnormalities, we decided to
investigate whether inhibition of LRRK2 expression was able to
alleviate the pathogenesis of mutant a-syn. To inhibit LRRK2
expression, we generated LRRK2 knockout (LRRK2/) mice
(Figure S11). LRRK2/ mice were viable, fertile, and displayed
no obvious motor behavioral phenotypes (Figure S12). No
apparent elevation of reactive astrocytosis, neurodegeneration,
or somatic accumulation of a-syn was found in brains of
20-month-old LRRK2/ mice (Figure S12; Tables 1, 2, and 3).
Furthermore, the levels of a-syn in TX-insol fraction appeared
comparable between LRRK2+/+ and LRRK2/ mice, indicating
that no apparent a-syn aggregates were formed in LRRK2/
mouse brains (data not shown). Compared with littermate
controls, only a moderate increase of activated microgliaFigure 8. Overexpression of A53T and LRRK2 Impairs the UPS Activiti
(A–C) Representative images show Ubi staining (arrows, green) in the cortex of A
G2019S (Ad), and nTg (Ae) mice at 6 months of age. Images from (Ba) to (Be) disp
overlay of Ubi and a-syn staining. Nuclei were labeled by Topro 3 staining (blue)
(D–F) Representative images show Ubi staining (arrows, green) in the cortex of LR
andA53T/G2019S (Dd) mice at 6 months of age, andG2019S mice at 20 (De) mon
while images from (Fa) to (Fe) show the overlay of Ubi and LRRK2 staining. Nucl
(G) Western blots show Ubi-positive HMW bands in the total brain homogenat
LRRK2WT, A53T, and A53T/LRRK2WT mice at 3 months of age; and nTg, A53T,
of monomeric Ubi (Ubi mono) with shorter exposure.
(H) Bar graph shows the ratio of HMW/Ubi mono in the total brain homogenat
**p < 0.01.(Figure S12; Table 2) was observed in the brains of 20-month-
old LRRK2/ mice.
To generate A53T mice in the LRRK2 knockout background
(A53T/LRRK2/), we intercrossed tetO-A53T/LRRK2+/ and
CaMKII-tTA/LRRK2+/ mice to get A53T/LRRK2/ and litter-
mate control mice. The neuropathology of A53T/LRRK2/ mice
and littermate controls was examined at 6 and 12 months of
age (Figure S13; Figure 10). Similarly to A53T/LRRK2+/+ mice,
12-month-old A53T/LRRK2+/ mice displayed significant neuro-
degeneration, astrocytosis, microgliosis, somatic accumulation
of a-syn, and severe fragmentation of the Golgi apparatus in
the striatum (Figure 10). In contrast, no apparent neurodegener-
ation was found in the striatum of age-matched littermate A53T/
LRRK2/ mice (Figure 10Ab; Table 1). The number of residual
neurons in the striatum of 12-month-old A53T/LRRK2/ is also
significantly more than that of age-matched A53T/LRRK2+/ and
A53T/LRRK2+/+ mice (Figure 10F). Moreover, no significant
elevation of astrocytosis, microgliosis, or somatic accumulation
of a-syn was detected in the striatum of 12-month-old A53T/
LRRK2/ mice (Figure 10; Tables 2 and 3). GLG1 staining
revealed normal morphology and distribution of the Golgi appa-
ratus in neurons ofA53T/LRRK2/ mice (Figures 10Eb and 10J).
Similar rescuing effects were also observed in the brains of
12-month-old A53T/LRRK2+/+ mice treated with DOX (A53T/
DOX) (Figure 10). Stereological analyses further revealed sig-
nificant reduction of neurodegeneration in A53T/DOX mice as
compared with that in age-matched A53T/LRRK2+/+ mice
(Figure 10F). In addition to immunohistological analyses, western
blots revealed a significant decrease of HMW a-syn in the total
brain homogenates of A53T/LRRK2/ mice as compared with
that in age-matchedA53T/LRRK2+/ mice (Figures 10G and 10I).
By contrast, only a moderate decrease of HMW-Ubi was
observed in A53T/LRRK2/ samples (Figure 10G), which did
not reach statistical significance by the densitometry analysis.
Together these findings demonstrate that inhibition of LRRK2
expression successfully ameliorated a-syn-mediated neuro-
pathological abnormalities in A53T transgenic mice.DISCUSSION
Mutations in a-syn or LRRK2 lead to typical PD-like neuropatho-
logical features such as the formation of LBs, a-syn-containing
cytoplasmic inclusions (Hardy et al., 2006). LRRK2 immunoreac-
tivity is also associated with LBs (Higashi et al., 2007; Zhu et al.,
2006). Furthermore, the expression of a-syn and LRRK2 appearses in Neurons
53T mice at 6 (Aa) and 20 (Ab) months of age, and A53T/LRRK2WT (Ac), A53T/
lay corresponding a-syn staining (red), while images from (Ca) to (Ce) show the
. Scale bar: 10 mm.
RK2WT (Da) and A53T/LRRK2WT (Db) mice at 6 months of age; G2019S (Dc)
ths of age. Images from (Ea) to (Ee) display corresponding LRRK2 staining (red),
ei were labeled by Topro 3 staining (blue).
es of nTg, A53T, G2019S, and A53T/G2019S mice at 1 month of age; nTg,
and G2019S mice at 18 months of age. The bottom panel in (G) shows the level
es of mice with different genotype at 1, 3, and 18 months of age. *p < 0.05,
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Figure 9. LRRK2 Exacerbates a-syn-Induced Mitochondrial Structural and Functional Abnormalities
(A–H) Representative EM images show mitochondria in the striatum of nTg (A and E), G2019S (B and F), A53T (C and G), and A53T/G2019S (D and H) transgenic
mice at 1 month of age. The abnormal mitochondria are marked by arrows (C and D). The dense matrix of the abnormal mitochondria in (G) and (H) often appears
‘‘sausage like’’ with multiple constrictions (large arrows in G and H) and concentric in arrangement, and occasionally became vesiculated (small double arrows in H).
n = 2 per genotype. Scale bar: 0.5 mm (A–D); 0.1 mm (E–H).
(I–L) Representative images showMitoSox Red staining in thestriatum ofnTg (I),G2019S (J),A53T (K), andA53T/G2019S (L)mice at 1 month of age. Scale bar: 50mm.
(M) Bar graph shows the quantification of MitoSox Red staining shown in (I)–(L). ##p < 0.001.
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Figure 10. Inhibition of LRRK2Delays the Progression of A53T a-syn-Mediated Neuropathology andReduces the Somatic Accumulation and
Aggregation of a-syn
(Aa–Ec) Representative images show c-caspase 3 (Aa–Ac), GFAP (Ba–Bc), Iba1 (Ca–Cc), a-syn (Da–Dc), and GLG1 (Ea–Ec) staining in the striatum of A53T/
LRRK2+/ and littermate A53T/LRRK2/ mice, and A53T/DOX mice at 12 months of age. The c-caspase-3-positive neuron (Aa), activated microglia (Ca),
and somatic accumulation of a-syn (Da) are indicated by arrows. The enlarged and a-syn-positive nerve terminals are labeled with arrowheads (Da and Db).
The striatum is outlined by TH staining (red, Ba–Bc). Nuclei were labeled by Topro 3 staining (blue). Scale bars: 100 mm (Ba–Bc), 50 mm (Aa–Ac), 20 mm
(Ca–Cc), and 10 mm (Da–Ec).
(F) Bar graph depicts the numbers of neurons remaining in the dorsal striatum of 12-month-old LRRK2+/+, A53T/LRRK2+/+, A53T/LRRK+/, A53T/LRRK2/, and
A53T/DOX mice. *p < 0.05, #p < 0.001.
(G and H) Western blots show HMW a-syn (G) and Ubi-positive bands (H) in the total homogenates from 12 month-oldA53T/LRRK2+/ andA53T/LRRK2/ mice.
(I) Densitometry analyses revealed significant reduction of HMW a-syn in the brain homogenates of 12-month-old A53T/LRRK2/ mice (n = 3) compared with
that of age-matched A53T/LRRK+/ mice (n = 4). *p < 0.05.
(J) Quantification of trans-Golgi morphology in striatal neurons (R300 per genotype) of mutant and control mice (R3 per genotype) at 12 months of age.
##p < 0.0001.
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These early studies indicate a potential pathophysiological
interplay between a-syn and LRRK2. To systematically investi-
gate whether a-syn and LRRK2 act synergistically in the patho-
genesis of PD, we generated and characterized a series ofcompound transgenic mice overexpressing PD-related A53T
a-syn mutant with various forms of LRRK2. Here we show that
LRRK2 regulated the progression of neuropathological abnor-
malities induced by A53T a-syn. Overexpression of either WT
or PD-associated G2019S LRRK2 greatly accelerated theNeuron 64, 807–827, December 24, 2009 ª2009 Elsevier Inc. 823
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cellular level, overexpression of LRRK2 impaired microtubule
dynamics and caused Golgi fragmentation, which we suspect
might exacerbate A53T a-syn-induced cytotoxicity via pro-
moting the abnormal somatic accumulation of a-syn. By con-
trast, genetic ablation of LRRK2maintained the normal organiza-
tion of Golgi complex, reduced the aggregation and somatic
accumulation of A53T a-syn, and thereby significantly delayed
the progression of A53T a-syn-induced neuropathology.
PD is clinically characterized as dyskinesia, resting tremor,
rigidity, and abnormal posture. The lack of obvious PD-like
behavioral phenotypes in our G2019S and A53T mutant mice
might be attributed to the scarce expression of exogenous
LRRK2 and a-syn transgenes in midbrain DA neurons under
the CaMKII promoter. Therefore, our present A53T and
G2019S transgenic mice are not ideal for studying the dysfunc-
tion of DA neurons. Nevertheless, they may serve as useful tools
to investigate the pathogenic mechanisms of PD-related mutant
LRRK2 and a-syn in vivo. Currently, we are in the process of
generating new lines of mice that overexpress G2019S LRRK2
or A53T a-syn in midbrain DA neurons. It would be interesting
to determine whether G2019S LRRK2 and A53T a-syn have
the same synergistic toxic effect when coexpressed in DA
neurons.
PD is pathologically characterized by the presence of a-syn-
containing inclusion bodies in the perinuclear area (Spillantini
et al., 1997). However, in normal neurons, a-syn is typically
enriched at axon terminals where it is associated with synaptic
vesicles (Maroteaux and Scheller, 1991; Tao-Cheng, 2006).
Like other synaptic vesicle proteins, the secretion of a-syn is
mediated by the ER-Golgi network, and a-syn is transported to
the axonal terminals by microtubule-based motor proteins (Roy
et al., 2008). Therefore, the formation of somatic inclusions of
a-syn may result from the dysfunction of ER-Golgi trafficking
and microtubule-based axonal transport (Cooper et al., 2006;
Gosavi et al., 2002). As an extension of these previous in vitro
observations, we found a significant increase in fragmented
Golgi apparatus in neurons of 6- and 12-month-old A53T a-syn
transgenic mice, which is correlated with an increased preva-
lence of neurons with somatic accumulation of a-syn. Interest-
ingly, overexpression of either WT or G2019S LRRK2 greatly
promoted the abnormal somatic accumulation of both the WT
and A53T a-syn in neurons. LRRK2 has been shown to associate
with Golgi complex (Biskup et al., 2006). While we did not
observe any substantial costaining of LRRK2 and Golgi in
LRRK2 transgenic neurons (data not shown), we found that over-
expression of LRRK2 caused significant fragmentation of Golgi
complex. Moreover, coexpression of LRRK2 and a-syn led to
more severe and synergistic fragmentation of the Golgi appa-
ratus, which was tightly correlated with the augmentation of
a-syn accumulation in the soma. By contrast, inhibition of
LRRK2 expression prevented the disintegration of Golgi com-
plex in A53T neurons and suppressed the accumulation of
a-syn in cell bodies. Our present study reveals a function of
LRRK2 in maintaining the normal organization of the Golgi
apparatus, and further demonstrates that the dysfunction of
ER-Golgi-mediated protein/vesicle trafficking may contribute
significantly to a-syn-induced pathogenesis in PD.824 Neuron 64, 807–827, December 24, 2009 ª2009 Elsevier Inc.In mammalian cells, the Golgi apparatus is composed of mul-
tiple layers of cisternal stacks juxtaposed with the microtubule
organization center in the vicinity of the nucleus, and microtu-
bules play an important role in maintaining the organization of
Golgi complex (Thyberg and Moskalewski, 1999). In line with
this notion, Lee et al. (2006) recently showed that a-syn coag-
gregates with microtubules and impairs microtubule-dependent
vesicle trafficking, which is proposed as a potential molecular
mechanism underlying a-syn-induced Golgi fragmentation in
cell cultures. Interestingly, LRRK2 has been shown to physically
interact with both a- and b-tubulin through its GTPase domain
(Gandhi et al., 2008; Gillardon, 2009). Various microtubule-
associated proteins, including tau, regulate the stability and
dynamics of microtubule network (Valiron et al., 2001). In line
with this notion, a recent report suggests that G2019S LRRK2
preferentially phosphorylates b-tubulin purified from brain
tissues and enhances the assembly of microtubules in the pres-
ence of other microtubule-associated proteins (Gillardon, 2009).
In contrast, the level of free tubulin is significantly increased
in the brain extract of LRRK2/ mice (Gillardon, 2009). In
agreement with these early observations, we found that the
level of RAB-insoluble tubulin was significantly elevated in the
brain homogenate of LRRK2 transgenic mice as compared
with that of nTg controls and A53T single transgenic mice,
whereas the level of RAB-S tubulin was dramatically decreased
in the brain homogenates of LRRK2 single and A53T/LRRK2
double transgenic mice. While the total levels of a- and b-tubu-
lin in the brain homogenates were not affected in LRRK2 trans-
genic mice, the altered ratio of RAB-S versus RAB-insoluble
tubulin in LRRK2-overexpressing neurons may reflect a deple-
tion of the free pool subunits and thereby a significant enhance-
ment of tubulin polymerization. Previous studies demonstrated
that treatment with taxol, a microtubule stabilizer, leads to
redistribution of microtubules in the cell and fragmentation of
the Golgi apparatus into areas of cell rich in microtubules (Weh-
land et al., 1983). Therefore, we suspect that a similar sequence
of events occurred in neurons overexpressing LRRK2, in which
LRRK2 increases of the ability of tubulin to polymerize, disrupts
the normal microtubule organization, and, consequently, alters
the normal distribution of Golgi complex. The fragmentation of
the Golgi apparatus per se may not cause overt cytotoxicity,
but it could impair the efficiency of coordinated vesicle traf-
ficking in mammalian cells (Thyberg and Moskalewski, 1999),
which may explain why overexpression of LRRK2 alone did
not cause any neurodegeneration despite apparent Golgi frag-
mentation, while LRRK2, together with A53T a-syn, dramatically
accelerated the abnormal somatic accumulation of a-syn and
associated cell loss. Together with previous in vitro studies
(Gandhi et al., 2008; Gillardon, 2009), our findings indicate
that LRRK2 is a stabilizer of microtubule assembly in cells
and that overexpression of LRRK2 promotes the additional
polymerization of tubulin in neurons, which we suspect might
lead to the fragmentation of the Golgi apparatus and exacer-
bate a-syn-induced ER-Golgi trafficking defects and other cyto-
toxicities.
The increased accumulation of a-syn in the soma may favor
the formation of a-syn aggregates, a key factor underlying its
toxicity to neurons (Conway et al., 1998; Narhi et al., 1999).
Neuron
LRRK2 and a-synuclein Double Transgenic MiceConcurrent with somatic accumulation of a-syn, more HMW and
detergent-insoluble a-syn was detected in the brain homoge-
nate of aged A53T and A53T/G2019S mice. Previous studies
indicate that a-syn aggregates cause proteasome impairment
(Tanaka et al., 2001), which may lead to the accumulation of
ubiquitinated proteins in neurons. Consistently, the levels of
ubiquitinated proteins were upregulated in A53T and aged
G2019S mice. Moreover, G2019S LRRK2 mutant protein was
sequestered as ubiquitin-positive clusters in neurons of aged
animals. We have shown earlier that the degradation of LRRK2
is primarily through the proteasomal pathway (Wang et al.,
2008). The accumulation of G2019S mutant and ubiquitin-posi-
tive protein aggregates in aged mice indicates that overexpres-
sion of LRRK2, especially the G2019S mutant, may impair
the UPS activities in neurons. Moreover, the presence of A53T
a-syn seemed to further damage the UPS activity and accelerate
the sequestration of LRRK2 G2019S aggregates. Although the
UPS activities were apparently impaired in neurons of A53T
mice, the dysfunction of UPS activities might not play a main
role in A53T-mediated neuropathogenesis in our mouse model,
since the inhibition of LRRK2 expression, which dramatically
delayed the progression of neurodegeneration in A53T mice,
only moderately reduced the accumulation of HMW ubiquiti-
nated proteins. These observations further support the notion
that the dysfunction of Golgi and microtubule-based molecule/
vesicle trafficking is likely a main pathogenic route of a-syn
and LRRK2-mediated neurodegeneration.
Extensive efforts have been devoted to identifying the potential
physiological substrates of LRRK2’s kinase activities (Imai et al.,
2008; Jaleel et al., 2007), although no formal link has been estab-
lished between the LRRK2’s kinase activities and the pathogen-
esis of PD. To further address whether the putative protein kinase
domain of LRRK2 is critical in regulating a-syn-mediated neuro-
pathology, we generated LRRK2 KD inducible transgenic mice
and crossbred them with A53T transgenic mice. Overexpression
of LRRK2 KD mutant also caused Golgi fragmentation and the
impairment of microtubule dynamics. When coexpressed with
A53T a-syn, LRRK2KD mutant promoted the somatic accumula-
tion of a-syn A53T mutant and accelerated A53T-mediated
neuropathology to a similar extent as LRRK2 WT protein did.
These data suggest that the kinase domain of LRRK2 is likely
not critical in accelerating A53T-induced neuropathological
abnormalities. Instead, the GTPase domain of LRRK2 may play
a more important role in LRRK2-induced damage to microtubules
and the Golgi apparatus through its direct association with micro-
tubules. It will be interesting to evaluate the role of LRRK2
GTPase domain in regulating the stability of microtubule network
and ER-Golgi trafficking in neurons, and its contribution to A53T
a-syn-mediated neurodegeneration.
In summary, we have revealed a function of LRRK2 in regu-
lating the intracellular trafficking and accumulation of a-syn in
neurons. Our data suggest that an excessive amount of LRRK2
or its mutants may impair the structure and function of Golgi
complex and microtubule-based transport, resulting in abnormal
somatic accumulation of a-syn, which may in turn contribute to
the accelerated progression of neuropathology induced by
a-syn A53T mutant. Generally, pathogenic proteins of human
origin need to be overly expressed in order to reproduce thedesired behavioral and pathological phenotypes in transgenic
mouse models, the fact of which also raises concerns of
disease-unrelated cytotoxicity. While an 8- to 16-fold increase
in LRRK2 protein expression in LRRK2WT and G2019S mice
greatly exacerbated a-syn A53T-mediated cytotoxicity, a
moderate increase of LRRK2 expression in both LRRK2WT-L
and KD mice also enabled promotion of a-syn A53T-induced
neurodegeneration. These findings suggest that the synergistic
cytotoxicity induced by coexpression of a-syn A53T and
LRRK2 could not be simply attributed to the excess expression
of LRRK2. Instead, our study indicates that LRRK2 may serve
a function in the regulation of the progression of a-syn A53T-
mediated neuropathological abnormalities. In support of this
notion, genetic inhibition of LRRK2 expression in a-syn A53T
transgenic mice significantly reduced the fragmentation of Golgi
complex and somatic accumulation of a-syn in neurons, and
effectively delayed the progression of a-syn A53T-mediated
neuropathological abnormalities. These results also suggest
that inhibition of LRRK2 expression may provide an applicable
therapeutic strategy to ameliorate a-syn-induced neurodegener-
ation in PD or other related neurodegenerative diseases.
EXPERIMENTAL PROCEDURES
Generation of LRRK2 and a-syn Inducible Transgenic Mice
and LRRK2/ mice
The generation of human WT and KD LRRK2, as well as WT and A53T a-syn
inducible transgenic mice, followed the same protocol as described previously
for the development of G2019S LRRK2 transgenic mice (Wang et al., 2008).
The LRRK2/ mice were generated through deletion of the second coding
exon of LRRK2 (Parisiadou et al., 2009). All mouse work follows the guidelines
approved by the Institutional Animal Care and Use Committees of the National
Institute of Child Health and Human Development.
Immunohistochemistry and Light Microscopy
Detailed information about immunohistochemical procedures is provided
in the Supplemental Data. Three or more animals per genotype and age
group were used for each study. Fluorescence images were captured using
a laser scanning confocal microscope (LSM 510; Zeiss, Thornwood, NJ).
The paired images in all of the figures were collected at the same gain and
offset settings. When postcollection processing was done, it was applied
uniformly to all paired images. The images of a-syn staining were presented
as a single optic layer after being acquired in z-series stack scans at 0.8 mm
intervals.
Stereology
Following standard stereotaxic coordinates (Paxinos and Franklin, 2001),
series of coronal sections across the dorsal striatum were processed for tyro-
sine hydroxylase (TH) and GFAP as well as TH and NeuN costaining. Three or
more animals per genotype and age group were used for each study. The
numbers of GFAP and NeuN-positive cells was assessed using Stereo Inves-
tigator 8 (MicroBrightField Inc, Williston, VT). The sampling scheme was
designed to have a coefficient of error (CE) of <10% in order to get reliable
results. All stereological analyses were performed under the 100 3 objective
of a Zeiss Axio microscope (Imager A1).
Extraction of Tubulin from Mouse Brains
As described previously (Ishihara et al., 1999), freshly dissected mouse brains
were homogenized in 2 ml/g of RAB (0.1M morpholineethanesulfonic acid
[MES], 1 mM EGTA, 0.75M NaCl, 0.02M NaF, 0.5 mM MgSO4, 1 mM PMSF,
and 100 mM EDTA) and protease inhibitors cocktail and centrifuged at
50,000 3 g for 1 hr. The pellets (RAB-P) were saved and the RAB-extractable
supernatants were boiled for 5 min and then chilled on ice for another 5 min.Neuron 64, 807–827, December 24, 2009 ª2009 Elsevier Inc. 825
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and the supernatants (RAB-S) were saved. After protein concentration was
determined using the BCA assay kit (Pierce), equal amount of proteins from
RAB-P and RAB-S fractions was analyzed by western blot.
Statistical Analysis
Statistical analysis was performed using Graphpad Prism 5 (Graphpad Soft-
ware Inc. La Jolla, CA) and StatView program (SAS Institute Inc.). Data are pre-
sented as means ± SEM. Statistical significances were determined by
comparing means of different groups using t test or ANOVA followed by
Post Hoc Tukey HSD test.
SUPPLEMENTAL DATA
Supplemental data for this article include Supplemental Experimental Proce-
dures and 13 figures and can be found at http://www.cell.com/neuron/
supplemental/S0896-6273(09)00889-7.
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